**HIN Engagement Form**

**About this form**

**Please read before completing this form:**

* This form helps us understand your innovation and the progress you have made to date.
* Please **do not** disclose any unprotected intellectual property in your responses.
* The information you provide will be used to assess **whether and how** we can support you.
* We will **not** share your information with other innovators or commercial companies unless you agree that we can do so.
* **You do not need to complete this form more than once.** If you have already submitted it as part of a NHS Innovation Service or another Health Innovation Network, please let us know which one.
* All data collected is subject to data protection and Information Governance regulations.

**Please note:**
By completing this form, you agree that your information will be shared with the 15 Health Innovation Networks and public sector partners, such as Department for Health and Social Care (DHSC), NHS England (NHSE) and the Office for Life Sciences (OLS). DHSC) to support innovation, research, and service improvement. For a full list of participating public sector organisations, please visit: <https://thehealthinnovationnetwork.co.uk/about-us/>

The reasons for data sharing include:

* Supporting the adoption and evaluation of health innovations
* Improving population health outcomes
* Facilitating knowledge exchange
* Enabling early uptake of new technologies
* Advancing research and service improvement where a legitimate or public interest applies

Any personal data shared by you is processed in line with UK GDPR. Identifiable data will only be used for marketing purposes if you have provided explicit consent.

**Please complete the form as fully as possible** to help us understand what support you may need.

**Mandatory questions are marked with an asterisk (\*).**

**NHS Innovation Service**

If you have already made a submission to the NHS Innovation Service, please enter the Innovation ID number here:

INN-\_ \_ \_ \_-\_ \_ \_ \_-\_

The rest of this form does not need to be completed before submission

**Relationship with sanctioned states**

If you are a sanctioned state (please see: <https://www.gov.uk/government/collections/uk-sanctions-regimes-under-the-sanctions-act>) do not complete this form as we are unable to work with you.

# **Organisation Details**

## **Contact Details (please enter all those that apply)**

|  |  |
| --- | --- |
| **\*Forename****\*Surname** |  Click here to enter text.  Click here to enter text.  |
| **\*Organisation** |  Click here to enter text.  |
| **\*Company Registration No. (or not applicable)** |  Click here to enter text.  |
| **Registered Address Line 1** |  Click here to enter text.  |
| **Registered Address City** |  Click here to enter text.  |
| **Registered Address County** |  Click here to enter text.  |
| **\*Registered Address Postcode** |  Click here to enter text.  |
| **Registered Address Country** |  Click here to enter text.  |
| **Telephone Number** |  Click here to enter text.  |
| **Email Address** |  Click here to enter text.  |
| **Website** |  Click here to enter text.  |
| **Parent company (if relevant)** |  Click here to enter text.  |

## **Organisation size \***

☐ Individual
☐ Micro (<10)
☐ Small (11–50)
☐ Medium (51–250)
☐ Large (251+)

## **Organisation type \***

 Academia

 Sole Trader

 Unincorporated Association

 Partnership

 Limited Partnership

 Trust

 Primary Care Network

 Integrated Care Board

 Local Authority

 Private company limited by shares

 Private company limited by guarantee

 Private unlimited company

 Public limited company

 Limited liability partnership

 Community interest company

 Charitable incorporated organisation

 Co-operative society

 Community benefit society

 Unknown

# **Summary of the innovation**

## **Name of the innovation (one innovation per application) \***

 Click here to enter text.

## **Innovation type \***

If you innovation meets multiple categories, please select all that apply which you consider to the biggest driver for your innovation.

 Medical device

 In vitro diagnostic

 Pharmaceutical

 Digital (including apps, platforms, software)

 Diagnostics

 Artificial intelligence (AI)

 Education or training of workforce

 Personal protective equipment (PPE)

 Models of care and clinical pathways

 Estates and facilities

 Travel and transport

 Food and nutrition

 Data and monitoring

 Service

 Therapeutics

 Unknown

 Other (please specify):\_\_\_\_\_\_\_\_\_\_\_

## **Please provide a brief description of the innovation, including its intended purpose, functionality (how it works), clinical setting/pathway, and the opportunity (size of intended patient group). \***

 Click here to enter text

## **What are the care settings for your innovation? (Please select up to 3 options that apply) \***

 Academia

 Acute Trust - Inpatient

 Acute Trust - Outpatient

 Ambulance

 Care Homes or Care setting

 Community Service

 Day Patient

 Dentistry

 End-of-life care (EOLC)

 ICS

 Industry

 Local Authority - Education

 Mental Health Trust

 Mental Health Community Services

 Optometry

 Person's home

 Pharmacies

 GP Primary Care

 Social Care

 Third Sector Organisations

 Urgent & Emergency

 Unknown

 Other (please specify): \_\_\_\_\_\_\_\_\_\_\_\_\_

## **Which of the areas below does your innovation impact most on? (please select all that apply) \***

|  |
| --- |
|  Non-clinical area Ageing Antimicrobial Stewardship Blood and immune system conditions Cancer Cardiovascular conditions Chronic and neuropathic pain Chronic fatigue syndrome CVD: AF/Stroke CVD: CKD CVD: Diabetes CVD: Heart Failure CVD: Lipids CVD: Obesity CVD: Hypertension Cystic fibrosis Diabetes and other endocrinal, nutritional and metabolic conditions Digestive tract conditions Disease Agnostic Ear, nose and throat conditions Eye conditions Fertility, pregnancy and childbirth Genomic Medicine Gynaecological conditions Immunology Infections Injuries, accidents and wounds Kidney conditions Liver conditions Mental health and behavioural conditions Mental Health: ADHD Mental Health: Autism Mental Health: Dementia Multiple long-term conditions Musculoskeletal conditions Neurological conditions Nutritional products Oral and dental health Pharmacy Primary Care Radiology or Imaging Respiratory: Other conditions Respiratory: Asthma Respiratory: COPD Respiratory: Infection Respiratory: Sleep and sleep conditions Sepsis Skin conditions Surgery Urological conditions Women’s Health Wound Management Unknown Other (please specify):\_\_\_\_\_\_\_\_\_\_\_\_\_ |

## **The current maturity of the innovation (please provide any relevant associated links or attachments)**

### **Readiness level (Please select all that apply)\***

|  |  |
| --- | --- |
| **1 Idea is formulated***The innovation is in its earliest stage of development. At this level, the idea exists as a conceptualisation, with the problem identified and a potential solution proposed. While the concept may be outlined and initial discussions about its feasibility may have begun, no practical work or development has taken place yet. The focus is on clarifying the problem, idea, defining its objectives, and hypothesising its potential impact.* |  ☐  |
| **2 Idea is explicitly described***The innovation has progressed beyond initial conceptualisation. At this stage, the idea is clearly articulated in detail, including its core components, intended functionality, and potential applications. There is a comprehensive understanding of the problem being addressed, and the proposed solution is well-defined. While no prototype or testing has occurred, the idea is documented and ready for initial stakeholder review or further development planning.* |  ☐  |
| **3 Experimental proof of concept***The innovation has progressed beyond initial ideas and theoretical concepts into an early stage of practical exploration. At this point, the core idea has been tested in a basic or simulated form to assess whether the solution is feasible. These initial tests or models aim to demonstrate that the underlying concept could function as intended, even if the solution is not yet fully developed or operational. This stage is focused on validating the fundamental assumptions behind the innovation, without requiring a complete or deployable prototype.* |  ☐  |
| **4 Elements of innovation validated in controlled environment (prototype)***The innovation progresses from experimental proof of concept to the creation and testing of a prototype. At this stage, individual components or subsystems of the innovation are integrated into a working prototype and tested under controlled conditions. This allows for the validation of critical elements, demonstrating that they function as intended when combined.* |  ☐  |
| **5 Whole innovation validated in controlled environment***The innovation has progressed to the point where the entire system, rather than individual components, is tested in a controlled environment. This stage focuses on integrating all elements of the innovation into a complete system and verifying its functionality as a cohesive unit under conditions designed to simulate real-world scenarios. The goal is to validate the innovation’s overall performance, reliability, and interoperability before testing it in an operational environment.* |  ☐  |
| **6 Whole innovation validated in real world environment***This should occur in a real-world setting, but with some degree of control to ensure the validation process can reliably assess whether the innovation functions as intended under practical conditions. It moves beyond the confines of a laboratory but still maintains a level of oversight to capture necessary data for validation. The purpose is to verify that the innovation can function correctly and achieve its intended outcomes under real-world conditions, which include the complexities and variations typical of the actual operational environment.* |  ☐  |
| **7 Whole innovation evaluated in real world environment** *This refers to the comprehensive assessment of the innovation's performance, impact, and user experience in an actual operational setting, reflecting the conditions in which the innovation is intended to be widely used. The purpose is to assess the overall effectiveness, user satisfaction, and integration of the innovation into existing systems or workflows. It focuses on understanding how the innovation performs in practice, beyond just functional correctness, and includes its real-world impact on users and processes.* |  ☐  |
| **8 Whole innovation demonstrated in real world environment***The innovation is showcased in its intended operational setting. At this stage, the innovation is deployed and operated in a real-world environment to demonstrate its capabilities, gather initial feedback, and build confidence among stakeholders. This phase focuses on proving that the innovation can function effectively outside controlled environments, though it may not yet be fully optimised or scaled for widespread use.* |  ☐  |
| **9 Whole innovation proven functional in multiple real world settings***The innovation has been deployed and validated in diverse operational environments. This stage demonstrates the reliability, adaptability, and scalability of the innovation across varying real-world conditions and use cases. The focus is on proving consistent functionality and performance in multiple settings, ensuring it meets the needs of a broader range of stakeholders.* |  ☐  |

**Which groups of end users were involved in designing, developing, or testing the innovation?**

**Select all that apply**

 Clinical or social care professionals working in the UK health and social care system

 Clinical or social care professionals working outside the UK

 Non-clinical healthcare staff

 Patients

 Service users

 Carers

 Other (please specify): \_\_\_\_\_\_\_\_\_\_\_\_\_

## **Please describe your stage of readiness e.g. Initial idea, Intellectual Property, user testing, proof of concept, early prototype, working prototype / pathway developed, clinical evidence (or equivalent), pilot / real-world evaluation \***

Click here to enter text.

## **Regulatory status / standards; including CE marking and classification, Digital Technology Assessment Criteria, ISO certification, etc (please select all that apply)**

ONLY tick the box if you have fully completed this and will be able to show us documentation confirming e.g. that you have a Class IIa medical device certificate.

**Not having achieved all appropriate regulatory standards will not exclude you from receiving appropriate HIN support.**

☐ UKCA/CE Class I medical device
☐ UKCA/CE Class IIa medical device
☐ UKCA/CE Class IIb medical device
☐ UKCA/CE Class III medical device
☐ In-vitro diagnostics (general)
☐ In-vitro diagnostics (self-test)
☐ In-vitro diagnostics (Annex II List B)
☐ In-vitro diagnostics (Annex II List A)
☐ Marketing authorisation
☐ CQC registration
☐ Digital Technology Assessment Criteria (DTAC)
☐ Pending
☐ Unknown
☐ Other (please specify):\_\_\_\_\_\_\_\_\_\_\_\_\_

# **Health innovation network engagement**

## **Have you already discussed this innovation with any of the health innovation networks? Please select all that apply**

☐ Health Innovation North East and North Cumbria
☐ Health Innovation Oxford and Thames Valley
☐ Health Innovation East Midlands
☐ Health Innovation South West
☐ Health Innovation East
☐ UCL Partners
☐ Health Innovation Manchester
☐ Health Innovation Wessex
☐ Health Innovation Network South London
☐ Health Innovation West Midlands
☐ Imperial College Health Partners
☐ Health Innovation West of England
☐ Health Innovation North West Coast
☐ Health Innovation Yorkshire and Humber
☐ Health Innovation Kent Surrey Sussex

## **If you have worked with any of the health innovation networks, please provide details of what support you have received and which organisation provided this.**

 Click here to enter text.

## **Please provide names of any contacts you have worked with at these health innovation networks**

 Click here to enter text.

## **What support are you seeking from the health innovation network? \***

 Click here to enter text.